|
gptkbp:instanceOf
|
gptkb:drug
small molecule
|
|
gptkbp:administeredBy
|
oral
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
2005
|
|
gptkbp:ATCCode
|
L01XE05
|
|
gptkbp:brand
|
gptkb:Nexavar
|
|
gptkbp:CASNumber
|
284461-73-0
|
|
gptkbp:category
|
protease inhibitor
antineoplastic agent
|
|
gptkbp:chemicalFormula
|
C21H16ClF3N4O3
|
|
gptkbp:contraindication
|
pregnancy
severe hepatic impairment
|
|
gptkbp:developedBy
|
gptkb:Bayer
gptkb:Onyx_Pharmaceuticals
|
|
gptkbp:eliminationHalfLife
|
25-48 hours
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
sorafenib
|
|
gptkbp:KEGGID
|
D06402
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
multi-kinase inhibitor
|
|
gptkbp:metabolism
|
gptkb:CYP3A4
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:PubChem_CID
|
216239
CHEMBL254
DB00398
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
diarrhea
fatigue
hypertension
rash
|
|
gptkbp:target
|
gptkb:PDGFR
gptkb:VEGFR
gptkb:RAF_kinase
|
|
gptkbp:UNII
|
81G40H8B0T
|
|
gptkbp:usedFor
|
gptkb:cancer
hepatocellular carcinoma
renal cell carcinoma
|
|
gptkbp:bfsParent
|
gptkb:RAF_kinase
gptkb:BRAF_gene
|
|
gptkbp:bfsLayer
|
5
|